STOP-VTE Study: Surgical Blood Clot Prevention in Cancer Patients

This observational study, called STOP-VTE, is looking at how doctors prevent blood clots (venous thromboembolism or VTE) after surgery for certain cancers. Specifically, it focuses on patients with cancer of the digestive system, female reproductive system, or genitourinary system. Researchers want to understand how often surgeons in the NCI Community Oncology Research Program (NCORP) network follow guidelines for extended blood clot prevention after abdominopelvic cancer surgery. The study will survey surgeons and advanced practice providers (APPs) about their practices and also look at factors that might influence these practices. The goal is to see if current guidelines are being used and to identify any challenges or helpful tools for preventing blood clots.

Study design
This is an observational study aiming to enroll 500 participants. It involves surveys and interviews with surgeons and surgical advanced practice providers.
What's involved
If you are a surgeon or surgical APP, you would complete a survey. Some participants may also be asked to do semi-structured interviews.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, evaluating self-reported utilization of blood clot prevention, is measured after one year from the start of Part 1.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07215624

Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study

Recruiting
Not specifiedAges 18+Observational
Wake Forest University Health Sciences
~500 participants
Updated 2026-04-08 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
59 of 59 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Self-reported utilization of guideline concordant ePPx for surgeons (Part 1)
Measured over After 1 year from start of Part 1
Malignant Digestive System Neoplasm
Malignant Female Reproductive System Neoplasm
Malignant Genitourinary System Neoplasm
59 sites across 16 states
Minnesota17
Missouri9
Iowa6
Michigan4
Wisconsin4
Delaware3
Georgia3
Maine2
  • Glenn Lesser, MD · STUDY_CHAIR · Wake Forest University Health Sciences

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

N/A
  • Self-reported utilization of guideline concordant ePPx for surgeons (Part 1)After 1 year from start of Part 1

    Will apply only to surgeons completing the Part 1 survey. Will be defined as answering "Yes, all cases or almost all cases" on the survey question asking about prescription of ePPx after discharge. The proportion of surgeons self-reporting utilization of guideline concordant ePPx will be estimated and reported along with an exact 95% confidence interval.